

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-80. Cancelled

81. (New) An isolated and purified TRAIL receptor (TRAIL-R) protein, wherein said isolated and purified TRAIL-R receptor protein is a product made by the process comprising the steps of:

- a. isolating plasma membranes from Jurkat cells;
- b. solubilizing and homogenizing said isolated plasma membranes of step (a);
- c. centrifuging said solubilized and homogenized isolated plasma membranes of step (b) to yield a plasma membrane extract and a pellet;
- d. applying said plasma membrane extract of step (c) to an anti-octapeptide monoclonal antibody affinity chromatography column, whereby said column of step (d) adsorbs non-specifically bound material and wherein said octapeptide has the sequence presented in SEQ ID NO: 5;
- e. applying column flow-through from step (d) to an octapeptide-TRAIL ligand affinity chromatography column, whereby said column of step (e) specifically binds said TRAIL-R receptor protein and wherein said octapeptide-TRAIL ligand is a fusion protein of said octapeptide having the sequence presented in SEQ ID NO:5 and TRAIL ligand;
- f. eluting fractions with substantial TRAIL ligand binding activity from said column of step (e); and,
- g. purifying said fractions of step (f) by reverse-phase HPLC to yield said isolated and purified TRAIL-R receptor protein, wherein said isolated and purified TRAIL-R receptor protein has a molecular weight of about 50 to 55 kilodaltons as determined by SDS polyacrylamide gel electrophoresis, and comprises an amino acid sequence VPANEGD (amino acids 327-333 of SEQ ID NO: 2).

82. (New) A composition comprising a plurality of isolated antibodies or antigen-binding fragments, wherein each of said antibodies or antigen-binding fragments of said plurality specifically binds to an isolated and purified TRAIL-R receptor protein of claim 81.
83. (New) The composition of claim 82, wherein said antibodies or antigen-binding fragments specifically bind to membranes of Jurkat cells.
84. (New) The composition of claim 83, wherein said antibodies or antigen-binding fragments specifically bind to the extracellular domain of TRAIL-R receptor (TRAIL-R) protein and wherein said antibodies or antigen-binding fragments block binding of TRAIL ligand to said TRAIL-R receptor protein.
85. (New) The composition claim 82, wherein said antibodies are monoclonal antibodies.
86. (New) The composition of claim 83, wherein said antibodies are monoclonal antibodies.
87. (New) The composition of claim 85, wherein said antibodies are humanized.
88. (New) The composition of claim 86, wherein said antibodies are humanized.
89. (New) A pharmaceutical composition comprising a composition of claim 82, in a physiologically acceptable excipient, diluent, or carrier.
90. (New) A pharmaceutical composition comprising a composition of claim 83, in a physiologically acceptable excipient, diluent, or carrier.
91. (New) A pharmaceutical composition comprising a composition of claim 85, in a physiologically acceptable excipient, diluent, or carrier.
92. (New) A pharmaceutical composition comprising a composition of claim 86, in a physiologically acceptable excipient, diluent, or carrier.
93. (New) A pharmaceutical composition comprising a composition of claim 87, in a physiologically acceptable excipient, diluent, or carrier.
94. (New) A pharmaceutical composition comprising a composition of claim 88, in a physiologically acceptable excipient, diluent, or carrier.
95. (New) A plurality of isolated anti-TRAIL-R receptor protein antibodies or antigen-binding fragments, wherein each of said antibodies or antigen-binding fragments of said plurality is specifically bound to a TRAIL-R receptor protein.

96. (New) The plurality of isolated anti-TRAIL-R receptor protein antibodies or antigen-binding fragments of claim 95, wherein said TRAIL-R receptor protein is an isolated TRAIL-R receptor protein.
97. (New) The plurality of isolated anti-TRAIL-R receptor protein antibodies or antigen-binding fragments of claim 95, wherein said TRAIL-R receptor protein is present on a cell membrane.
98. (New) The plurality of isolated anti-TRAIL-R receptor protein antibodies or antigen-binding fragments of claim 95, wherein said antibodies are monoclonal antibodies.
99. (New) The plurality of isolated anti-TRAIL-R receptor protein antibodies or antigen-binding fragments of claim 98, wherein said antibodies are humanized.
100. (New) A composition comprising a plurality of isolated monoclonal antibodies or antigen-binding fragments thereof, wherein each of said antibodies or antigen-binding fragments of said plurality specifically bind to a TRAIL receptor (TRAIL-R) protein, said antibodies made by the process of:
- a. immunizing a mouse with an isolated and purified TRAIL receptor (TRAIL-R) protein of claim 81;
 - b. generating hybridomas by fusing murine myeloma cells with spleen cells obtained from said immunized mouse of step (a);
 - c. screening said hybridomas of step (b) for reactivity to purified TRAIL-R receptor protein;
 - d. isolating and purifying a plurality of monoclonal antibodies expressed by said hybridomas of step (c), wherein said monoclonal antibodies specifically bind to said TRAIL-R receptor protein.
101. (New) The composition of claim 100, wherein said monoclonal antibodies are humanized.
102. (New) A pharmaceutical composition comprising a composition 100, in a physiologically acceptable excipient, diluent, or carrier.
103. (New) A pharmaceutical composition comprising a composition 101, in a physiologically acceptable excipient, diluent, or carrier.

104. (New) The isolated and purified TRAIL receptor (TRAIL-R) protein of claim 81, further comprising the sequence of SEQ ID NO: 4.
105. (New) A composition comprising a plurality of isolated antibodies or antigen-binding fragments, wherein each of said antibodies or antigen-binding fragments of said plurality specifically binds to an isolated TRAIL-R protein of claim 104.
106. (New) The composition of claim 105, wherein said antibodies or antigen-binding fragments specifically bind to membranes of Jurkat cells, and wherein said Jurkat cells are expressing TRAIL-R receptor protein.
107. (New) The composition of claim 106, wherein said antibodies specifically bind to the extracellular domain of TRAIL receptor (TRAIL-R) protein and wherein said antibodies block binding of TRAIL ligand to said TRAIL-R receptor protein.
108. (New) The composition claim 105, wherein said antibodies are monoclonal antibodies.
109. (New) The composition claim 106, wherein said antibodies are monoclonal antibodies.
110. (New) The composition of claim 108, wherein said antibodies are humanized.
111. (New) The composition of claim 109, wherein said antibodies are humanized.
112. (New) A pharmaceutical composition comprising a composition of claim 105, in a physiologically acceptable excipient, diluent, or carrier.
113. (New) A pharmaceutical composition comprising a composition of claim 106, in a physiologically acceptable excipient, diluent, or carrier.
114. (New) A pharmaceutical composition comprising a composition of claim 108, in a physiologically acceptable excipient, diluent, or carrier.
115. (New) A pharmaceutical composition comprising a composition of claim 109, in a physiologically acceptable excipient, diluent, or carrier.
116. (New) A pharmaceutical composition comprising a composition of claim 110, in a physiologically acceptable excipient, diluent, or carrier.
117. (New) A pharmaceutical composition comprising a composition of claim 111, in a physiologically acceptable excipient, diluent, or carrier.